Eli Lilly and Company (LLY)

Table of Contents

Intro and Overview

Introduction

Business Overview

Trends and Forces

Corporate Overview (cont.)

Key Trends and Forces

Competition

Competition

Zyprexa competes with Pfizer's Geodon, AstraZeneca's Seroquel, Johnson & Johnson's Risperdal, and Bristol-Myers Squibb's Abilify in the antipsychotics market. A studied showed Zyprexa to be most effective in its class,^[1] but the drug causes significant weight gain^[2] while Geodon does not.^[3]

Cymbalta competes with Forest Laboratories' Lexapro and Wyeth's Effexor in the antidepressant market, and Pfizer's Lyrica for diabetic neuropathy.^[1]

Evista and Forteo compete with Merck's Fosamax and Novartis's Zometa in the osteoporosis market.^[1] Amgen's Denosumab is a new contender in late stage clinical trials and may soon enter the market.

Gemzar competes with numerous chemotherapy agents, but is more tolerable than older drugs while retaining effectiveness.^[1]

Humalog competes with other insulin analogs made by Novo Nordisk and Sanofi-Aventis to treat diabetes.^[4] Insulin analogs mimic the role of natural insulin in regulating blood sugar and are generally all very similar in action.

Cialis competes with Pfizer's Viagra and Bayer's Levitra in the erectile dysfunction (ED) drug market. Cialis's primary competitive advantage is that it is effective for up to 36 hours on one dose, compared to the other drugs, which must be taken a short time before anticipated sexual activity.^[5]

Pharmaceutical and Biotech Industry — Competitive Operating Metrics (2008)	JOHNSON & JOHNSON (JNJ)	Pfizer (PFE)	Novartis AG (NVS)	Abbott Laboratories (ABT)	Merck (MRK)	Bristol-Myers Squibb Company (BMY)	Eli Lilly and Company (LLY)	Amgen (AMGN)	Allergan (AGN)	AstraZeneca (AZN)
Revenue (billions of USD)
Total Revenue	63.75	48.30	42.58	29.53	23.85	20.60	20.38	15.00	4.40	31.60
Gross Revenue	45.24	40.18	30.02	16.92	18.27	14.20	16.00	12.71	3.58	25.41
Revenue Growth from 2007	4.34%	0.00%	9.34%	13.94%	-1.44%	13.21%	9.41%	1.55%	11.81%	6.90%
Income
Net Income	12.95	8.10	8.20	4.88	7.81	4.15	(2.07)	4.20	0.58	6.10
Net Profit Margin	20.31%	16.78%	19.24%	16.53%	32.74%	20.15%	-10.17%	27.97%	13.15%	19.31%
Operating Income	16.93	9.69	8.80	5.69	9.81	5.47	(1.31)	5.21	0.80	9.14
Earnings per Share	4.63	2.03	3.58	3.10	4.02	1.87	3.70	4.19	2.06	4.63

Introduction and Overview | Trends and Forces | Competition

References

1. ↑ ^{1.0 1.1 1.2 1.3} Cowen and Company. Therapeutic Categories Outlook. March 2008.
2. ↑ Wikipedia:Zyprexa
3. ↑ Wikipedia:Geodon
4. ↑ Wikipedia:Insulin analogue
5. ↑ Wikipedia:Cialis

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.